WO2022012531A1 - Procédé de préparation d'une cellule immunitaire modifiée - Google Patents

Procédé de préparation d'une cellule immunitaire modifiée Download PDF

Info

Publication number
WO2022012531A1
WO2022012531A1 PCT/CN2021/106007 CN2021106007W WO2022012531A1 WO 2022012531 A1 WO2022012531 A1 WO 2022012531A1 CN 2021106007 W CN2021106007 W CN 2021106007W WO 2022012531 A1 WO2022012531 A1 WO 2022012531A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cells
nucleic acid
cell
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/106007
Other languages
English (en)
Chinese (zh)
Inventor
贾璐盈
林彦妮
袁慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cure Genetics Co Ltd
Original Assignee
Cure Genetics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cure Genetics Co Ltd filed Critical Cure Genetics Co Ltd
Publication of WO2022012531A1 publication Critical patent/WO2022012531A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Definitions

  • the present application relates to the field of biomedicine, in particular to a method for preparing a universal chimeric antigen T cell, including knocking out Fas protein and transferring FasL protein.
  • the method comprises administering a Cas protein to the immune cell.
  • the CD24 protein comprises the amino acid sequence set forth in SEQ ID NO:59.
  • the vector comprises a viral vector.
  • the present application provides a population of cells comprising said immune cells, wherein at least 20% of the immune cells in said cell population do not substantially express Fas and at least 5% of the immune cells overexpress FasL.
  • Figure 5 shows the fold expansion of the modified immune cells described in the present application and allogeneic T cells co-cultured on day 6.
  • Figure 7 shows the expansion fold of the modified immune cells described in the present application after co-culture with allogeneic T cells.
  • gene silencing generally refers to the inhibition of the expression of a gene, which can be inhibited by blocking the transcription or translation of the gene.
  • chimeric antigen receptor generally refers to a fusion protein comprising an extracellular domain capable of binding an antigen and at least one intracellular domain.
  • CAR is the core component of chimeric antigen receptor T cells (CAR-T), which can include targeting moieties (eg, moieties that bind tumor-associated antigens (TAAs)), hinge regions, transmembrane regions, and cells internal domain.
  • targeting moieties eg, moieties that bind tumor-associated antigens (TAAs)
  • TAAs tumor-associated antigens
  • CRISPR/Cas system or “CRISPR-Cas system” generally refers to a nuclease system consisting of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-related proteins (i.e. Cas proteins), It can cut almost all genomic sequences adjacent to the protospacer-adjacent motif (PAM) in eukaryotic cells.
  • CRISPR/Cas system may be used to collectively refer to transcripts involving CRISPR-associated (“Cas”) genes, as well as other elements involved in their expression or directing their activity, and may include sequences encoding Cas genes, tracr (transactivating CRISPR) sequences (e.g.
  • the present application provides a method for preparing a modified immune cell, the modification comprising the steps of: a) down-regulating the expression and/or activity of Fas protein in the immune cell, b) up-regulating the expression and/or activity of the Fas protein in the immune cell FasL protein expression and/or activity such that Fas protein expression and/or activity in the modified immune cells is reduced or eliminated compared to immune cells without the modification, and the modified Elevated expression and/or activity of FasL protein in immune cells.
  • the method can include administering to the immune cell one or more substances selected from the group consisting of antisense RNA, siRNA, shRNA, CRISPR/Cas systems, RNA editing systems such as RNA adenosine deaminase (ADAR), RNA-Guided Endonuclease, Zinc Finger Nuclease (ZFN), Mega-TAL Nuclease, Transcription Activator-Like Effector Nuclease (TALEN), Meganuclease, Base Editing, CRISPR interference (or CRISPRi), and, Zinc finger gene repressor and/or transcription activator-like effector (TALE) gene repressor-mediated transcriptional repression.
  • the method may include administering to immune cells using inhibitory proteins, which may include substances capable of inhibiting the activity or function of the Fas protein, eg, inhibitory ligands, receptors, antibodies of the Fas protein and/or enzymes.
  • the target polynucleotide of the CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide can be a polynucleotide that resides in the nucleus of a eukaryotic cell.
  • the backbone sequence of the present application can be derived from the backbone sequence described in PCT application publication WO2019011118A1, for example, can be the nucleotide sequence shown in any one of SEQ ID NOs: 34-45 (listed as 5' to 3') , where the first region in lowercase font represents the tracr mate sequence, and the second region in lowercase font represents the tracr sequence, and the last poly-U sequence represents the transcription terminator.
  • the number of U in the poly-U is not limited to what is shown in this example, and can be increased or decreased. In some cases, poly-U can be removed without affecting activity.
  • a crRNA targeting a nucleic acid molecule encoding a Fas protein described herein may comprise at least 80% (eg, at least 85%, at least 90%) of the nucleotide sequence set forth in any one of SEQ ID NOs: 1-15 %, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100%) nucleotides of sequence identity sequence.
  • proteins that can be fused to Cas proteins include, but are not limited to, epitope tags, reporter genes, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity.
  • the FasL protein may also comprise a hinge region.
  • the hinge region may contain fewer protease cleavage sites than the hinge region of the native FasL protein.
  • the hinge region may be a hinge region derived from a transmembrane protein other than FasL.
  • the hinge region may be a hinge region derived from the tumor necrosis factor superfamily.
  • the hinge region can be a hinge region derived from TNFSF10 or OX40L.
  • nucleic acid molecules described herein can also be linked to many types of vectors.
  • the nucleic acid can be ligated to, including but not limited to, plasmids, phagemids, phages, viruses and/or cosmids.
  • Particular vectors of interest can include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.
  • the methods of the present application may comprise introducing the vectors described herein into immune effector cells.
  • the vectors described herein can be introduced into the immune effector cells, such as T lymphocytes, B cells, macrophages, or natural killer (NK) cells.
  • each or each cell may comprise one or one of the vectors described herein.
  • each or each cell may comprise a plurality (eg, 2 or more) or more (eg, 2 or more) of the vectors described herein.
  • the vectors described herein can be introduced into the cells.
  • immune effector cells can be transfected with a retroviral vector, and the viral genome with the nucleic acid encoding the fusion protein can be integrated into the host genome to ensure long-term and stable expression of the target gene.
  • a transposon using a transposon, a plasmid carrying a nucleic acid encoding the fusion protein and a plasmid carrying a transposase are introduced into target cells.
  • Gene or protein expression levels can be detected by a variety of methods, including methods at the nucleic acid level (including by reverse transcriptase polymerase chain reaction (RT-PCR) or by Southern blotting, in situ hybridization for mRNA quantification, next-generation sequencing ) and methods at the protein level (including immunofluorescence labeling and analysis by flow cytometry, histochemistry, immunoblot analysis, and in vitro binding studies).
  • RT-PCR reverse transcriptase polymerase chain reaction
  • protein expression levels can be quantified by ELISA techniques well known to those skilled in the art. Quantitative measurements can be done using a number of standard assays. For example, transcript levels can be measured using RT-PCR and hybridization methods including RNase protection, Southern blot analysis, RNA dot analysis. Immunohistochemical staining and flow cytometry, Western blot analysis can also be used to assess whether and how much Fas protein and/or Fas gene is present.
  • FasL and its variants FasL-M1 and FasL-M2 can protect allogeneic T cells from killing, so that T cells expressing FasL, FasL-M1 and FasLF-M2 can survive more under the killing effect of allogeneic T cells. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de préparation d'une cellule immunitaire modifiée. La modification comprend les étapes suivantes : a) la réduction de l'expression et/ou de l'activité d'une protéine Fas dans la cellule immunitaire, et b) l'augmentation de l'expression et/ou de l'activité d'une protéine FasL dans la cellule immunitaire. Ainsi, par rapport à une cellule immunitaire qui n'est pas soumise à la modification, l'expression et/ou l'activité de la protéine Fas dans la cellule immunitaire modifiée sont réduites ou supprimées, et l'expression et/ou l'activité de la protéine FasL dans la cellule immunitaire modifiée sont augmentées.
PCT/CN2021/106007 2020-07-14 2021-07-13 Procédé de préparation d'une cellule immunitaire modifiée Ceased WO2022012531A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010676239 2020-07-14
CN202010676239.6 2020-07-14

Publications (1)

Publication Number Publication Date
WO2022012531A1 true WO2022012531A1 (fr) 2022-01-20

Family

ID=79556017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/106007 Ceased WO2022012531A1 (fr) 2020-07-14 2021-07-13 Procédé de préparation d'une cellule immunitaire modifiée

Country Status (1)

Country Link
WO (1) WO2022012531A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187663A1 (fr) * 2021-03-04 2022-09-09 Allogene Therapeutics, Inc. Expression de fasl et inactivation du gène fasr pour protéger les cellules thérapeutiques contre le rejet allogénique et la mort cellulaire induite par activation
WO2024064637A3 (fr) * 2022-09-19 2024-05-16 Emendobio Inc. Inactivation biallélique de faslg
JP2025504722A (ja) * 2022-01-25 2025-02-18 上海邦耀生物科技有限公司 修飾細胞及びその使用
WO2025261231A1 (fr) * 2024-06-17 2025-12-26 天海元祺生物科技(天津)有限公司 Arnsg ciblant fortement le gène hla-a humain, composition associée et utilisation associée

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020308A1 (fr) * 1997-10-23 1999-04-29 Biocrystal Ltd. Procede pour inhiber les metastases et la croissance des cellules tumorales par modulation clinique de l'expression tumorale du ligand fas
CN103215223A (zh) * 2013-03-18 2013-07-24 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN104046593A (zh) * 2013-03-14 2014-09-17 浙江大学 一种低免疫原性的人细胞及其制备方法
CN104822384A (zh) * 2012-03-30 2015-08-05 南加州大学 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
CN106480027A (zh) * 2016-09-30 2017-03-08 重庆高圣生物医药有限责任公司 CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA
CN107206024A (zh) * 2014-10-31 2017-09-26 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
CN109722437A (zh) * 2018-12-29 2019-05-07 广州百暨基因科技有限公司 一种通用型car-t细胞及其制备方法和用途
US20190345446A1 (en) * 2018-04-25 2019-11-14 The Broad Institute, Inc. Compositions and methods for modulating th-17 and th-1 cell balance
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020308A1 (fr) * 1997-10-23 1999-04-29 Biocrystal Ltd. Procede pour inhiber les metastases et la croissance des cellules tumorales par modulation clinique de l'expression tumorale du ligand fas
CN104822384A (zh) * 2012-03-30 2015-08-05 南加州大学 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
CN104046593A (zh) * 2013-03-14 2014-09-17 浙江大学 一种低免疫原性的人细胞及其制备方法
CN103215223A (zh) * 2013-03-18 2013-07-24 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN107206024A (zh) * 2014-10-31 2017-09-26 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
CN106480027A (zh) * 2016-09-30 2017-03-08 重庆高圣生物医药有限责任公司 CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA
US20190345446A1 (en) * 2018-04-25 2019-11-14 The Broad Institute, Inc. Compositions and methods for modulating th-17 and th-1 cell balance
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
CN109722437A (zh) * 2018-12-29 2019-05-07 广州百暨基因科技有限公司 一种通用型car-t细胞及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. DRANITZKI-ELHALEL, J. H. HUANG, M. SASSON, J. RACHMILEWITZ, M. PARNAS AND M. L. TYKOCINSKI: "CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 19, no. 4, 1 April 2007 (2007-04-01), GB , pages 355 - 363, XP002668353, ISSN: 0953-8178, DOI: 10.1093/INTIMM/DXM001 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187663A1 (fr) * 2021-03-04 2022-09-09 Allogene Therapeutics, Inc. Expression de fasl et inactivation du gène fasr pour protéger les cellules thérapeutiques contre le rejet allogénique et la mort cellulaire induite par activation
US12577290B2 (en) 2021-03-04 2026-03-17 Allogene Therapeutics, Inc. FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
JP2025504722A (ja) * 2022-01-25 2025-02-18 上海邦耀生物科技有限公司 修飾細胞及びその使用
EP4469579A4 (fr) * 2022-01-25 2025-10-29 Brl Medicine Inc Cellules modifiées et leurs utilisations
WO2024064637A3 (fr) * 2022-09-19 2024-05-16 Emendobio Inc. Inactivation biallélique de faslg
WO2025261231A1 (fr) * 2024-06-17 2025-12-26 天海元祺生物科技(天津)有限公司 Arnsg ciblant fortement le gène hla-a humain, composition associée et utilisation associée

Similar Documents

Publication Publication Date Title
WO2020092057A1 (fr) Compositions et procédés de génération rapide et modulaire de lymphocytes t récepteurs d'antigènes chimériques
WO2022012531A1 (fr) Procédé de préparation d'une cellule immunitaire modifiée
KR20200133219A (ko) 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
CN111909966B (zh) 一种制备经修饰的免疫细胞的方法
CN114901808A (zh) 生产car-t细胞的方法
JP2023538303A (ja) 所望の表現型を有するｃａｒ ｔ細胞の操作および選択のための組成物および方法
KR20180092989A (ko) 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
JP2024502036A (ja) 操作されたｔ細胞
EP3917546A1 (fr) Compositions de régulation génique et procédés pour améliorer l'immunothérapie
KR20230036059A (ko) 표적 핵산을 변형시키는 조성물 및 방법
JP2023517326A (ja) フォークヘッドボックスｐ３（ｆｏｘｐ３）遺伝子発現をモジュレートするための組成物および方法
EP3377086B1 (fr) Hétérodimères dans l'immunité de l'interleukine 12b (p40) de type antigène lymphocytaire cd5 (cd5l)
CN117120062A (zh) 用于发现cd8 t细胞中治疗靶标的体内crispr筛选系统
EP4370676A2 (fr) Compositions et procédés de ciblage, d'édition ou de modification de gènes humains
US20250032542A1 (en) Systems and methods for trans-modulation of immune cells by genetic manipulation of immune regulatory genes
EP4593847A1 (fr) Inhibition de stress génotoxique pour améliorer l'ingénierie des lymphocytes t
US20250270546A1 (en) Guide rnas and uses thereof
WO2023173137A1 (fr) Compositions et méthodes de modification génétique efficace et stable de cellules eucaryotes
US20240325537A1 (en) Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
JP2025510686A (ja) 細胞治療
HK40103142A (zh) 用於发现cd8 t细胞中治疗靶标的体内crispr筛选系统
WO2026003069A1 (fr) Constructions et vecteurs pour la reprogrammation de cellules en cellules cdc1, compositions et procédés associés
HK40097024A (zh) 用於工程改造和选择具有期望表型的car t细胞的组合物和方法
CN120943975A (zh) 一种敲低dmgdh基因表达的嵌合抗原受体及其应用
HK1254123B (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21842674

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21842674

Country of ref document: EP

Kind code of ref document: A1